Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)—a trial by the Asian Myeloma Network

Pomalidomide is a third generation immunomodulatory drug which in combination with dexamethasone, has been shown to be active in relapsed/refractory multiple myeloma. However, the data in Asian patients remain limited. We conducted a prospective phase two clinical trial in major cancer centers in Si...

Descripción completa

Detalles Bibliográficos
Autores principales: Soekojo, Cinnie Yentia, Kim, Kihyun, Huang, Shang-Yi, Chim, Chor-Sang, Takezako, Naoki, Asaoku, Hideki, Kimura, Hideo, Kosugi, Hiroshi, Sakamoto, Junichi, Gopalakrishnan, Sathish Kumar, Nagarajan, Chandramouli, Wei, Yuan, Moorakonda, Rajesh, Lee, Shu Ling, Lee, Je Jung, Yoon, Sung-Soo, Kim, Jin Seok, Min, Chang Ki, Lee, Jae-Hoon, Durie, Brian, Chng, Wee Joo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783445/
https://www.ncbi.nlm.nih.gov/pubmed/31594919
http://dx.doi.org/10.1038/s41408-019-0245-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783445/
https://www.ncbi.nlm.nih.gov/pubmed/31594919
http://dx.doi.org/10.1038/s41408-019-0245-1

Ejemplares similares